GlassScriptPhysician profile
Samuel B Jonnalagadda
NPI 1427147628
$4,747.32
in general payments reported to CMS, 2019-2025
36 companies · $730 in 2025
The $730 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $582 · 2020: $568 · 2021: $946 · 2022: $754 · 2023: $652 · 2024: $516 · 2025: $730.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,898.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,898.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $736.12 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $509.28 | 2021-2025 | |
| Pfizer INC. | $501.90 | 2019-2025 | |
| Lilly USA, LLC | $435.49 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $394.79 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Amgen INC. | $250.56 | 2020-2025 | Repatha, Otezla, Repatha |
| Glaxosmithkline, LLC. | $208.61 | 2021-2025 | Trelegy Ellipta |
| Biohaven Pharmaceuticals, INC. | $194.71 | 2020-2021 | |
| Astellas Pharma US INC | $178.28 | 2019-2025 | Veozah |
| Dexcom, INC. | $158.54 | 2021-2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $149.67 | 2021-2025 | Freestyle Libre 3 |
| Teva Pharmaceuticals USA, INC. | $136.88 | 2019-2023 | Ajovy |
| Sumitomo Pharma America, INC. | $120.42 | 2024-2025 | Gemtesa, Myfembree |
| Boehringer Ingelheim Pharmaceuticals, INC. | $92.95 | 2019-2023 | Jardiance |
| Amarin Pharma, INC. | $69.79 | 2020-2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $58.63 | 2020-2021 | |
| Phathom Pharmaceuticals, INC. | $57.49 | 2025 | Voquezna |
| Allergan, INC. | $54.31 | 2020 | |
| Noven Therapeutics, LLC | $52.74 | 2025 | Xelstrym |
| Exact Sciences Corporation | $46.30 | 2025 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $44.97 | 2022 | |
| Genentech USA, INC. | $35.47 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $33.89 | 2023-2025 | Nuedexta, Rexulti |
| Bausch Health US, LLC | $30.81 | 2019-2022 | |
| Circassia INC. | $27.88 | 2019 | |
| Eisai INC. | $21.83 | 2021 | |
| Alexion Pharmaceuticals, INC. | $20.59 | 2023 | Strensiq |
| Sanofi-Aventis U.S. LLC | $17.21 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $16.61 | 2025 | Eliquis |
| Sanofi Pasteur INC. | $15.89 | 2019 | |
| Janssen Pharmaceuticals, INC | $14.24 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $13.29 | 2022 | |
| Currax Pharmaceuticals LLC | $13.13 | 2023 | Contrave |
| Merck Sharp & Dohme LLC | $11.51 | 2020 | |
| Novartis Pharmaceuticals Corporation | $11.38 | 2019 | |
| Melinta Therapeutics, LLC | $11.16 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Jonnalagadda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.